Vanda Pharma: High Risk, Heavily Discounted - Stock Ahead Of PDUFA This Week

Group 1 - Vanda Pharmaceuticals Inc. reported a disappointing 4Q25 with a GAAP EPS of -$2.39, missing consensus by approximately $1.07 [1] - The company's revenue for the quarter was $57.22 million, which fell short of expectations by about $2.05 million [1] Group 2 - The article emphasizes the importance of evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities in the biotech sector [1] - It highlights the need for careful scrutiny in biotech investments, where breakthrough science can lead to significant returns but also carries inherent risks [1]